- Home
- CHI vs OCS Comparison
CHI vs OCS Comparison
Compare CHI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- OCS
- Stock Information
- Founded
- CHI 2002
- OCS 2003
- Country
- CHI United States
- OCS Switzerland
- Employees
- CHI N/A
- OCS N/A
- Industry
- CHI Investment Managers
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- OCS Health Care
- Exchange
- CHI Nasdaq
- OCS Nasdaq
- Market Cap
- CHI 696.7M
- OCS 689.8M
- IPO Year
- CHI N/A
- OCS N/A
- Fundamental
- Price
- CHI $10.19
- OCS $18.58
- Analyst Decision
- CHI
- OCS Strong Buy
- Analyst Count
- CHI 0
- OCS 4
- Target Price
- CHI N/A
- OCS $31.50
- AVG Volume (30 Days)
- CHI 186.2K
- OCS 28.3K
- Earning Date
- CHI 01-01-0001
- OCS 05-08-2025
- Dividend Yield
- CHI 9.90%
- OCS N/A
- EPS Growth
- CHI N/A
- OCS N/A
- EPS
- CHI N/A
- OCS N/A
- Revenue
- CHI N/A
- OCS $847,333.00
- Revenue This Year
- CHI N/A
- OCS $49.27
- Revenue Next Year
- CHI N/A
- OCS $1,920.31
- P/E Ratio
- CHI N/A
- OCS N/A
- Revenue Growth
- CHI N/A
- OCS N/A
- 52 Week Low
- CHI $9.70
- OCS $10.79
- 52 Week High
- CHI $11.61
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- CHI 58.91
- OCS 54.68
- Support Level
- CHI $10.00
- OCS $18.01
- Resistance Level
- CHI $10.21
- OCS $19.50
- Average True Range (ATR)
- CHI 0.16
- OCS 0.77
- MACD
- CHI 0.06
- OCS 0.17
- Stochastic Oscillator
- CHI 92.77
- OCS 66.30
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.